SNDX Syndax Pharmaceuticals, Inc
Syndax Pharmaceuticals, Inc (SNDX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 72% planned / 28% discretionary
Largest single sale: $784.8K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer | Sell 10b5-1 | 32,375 | $24.24 | $784.8K | 484,843 −6.3% of holding | |
| Botwood Nicholas A.J. | Head of R&D, CMO | Sell 10b5-1 | 31,235 | $18.14 | $566.6K | 60,885 −33.9% of holding | |
| Botwood Nicholas A.J. | Head of R&D, CMO | Sell 10b5-1 | 34,280 | $18.00 | $617.0K | 60,885 −36% of holding | |
| Metzger Michael A | Chief Executive Officer | Sell | 6,847 | $18.99 | $130.0K | 484,843 −1.4% of holding | |
| Goldan Keith A. | Chief Financial Officer | Sell | 1,177 | $18.99 | $22.4K | 139,252 −0.8% of holding | |
| Metzger Michael A | Chief Executive Officer | Sell | 17,159 | $21.03 | $360.8K | 491,690 −3.4% of holding | |
| Goldan Keith A. | Chief Financial Officer | Sell | 3,410 | $21.03 | $71.7K | 140,429 −2.4% of holding | |
| Metzger Michael A | Chief Executive Officer | Sell | 7,412 | $20.62 | $152.8K | 508,849 −1.4% of holding | |
| Goldan Keith A. | Chief Financial Officer | Sell | 2,082 | $20.62 | $42.9K | 143,839 −1.4% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.